Gamco Investors INC. ET AL Invests $1.96 Million in Ignyta Inc (RXDX)
Gamco Investors INC. ET AL purchased a new stake in Ignyta Inc (NASDAQ:RXDX) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 73,250 shares of the biopharmaceutical company’s stock, valued at approximately $1,956,000.
Several other institutional investors have also bought and sold shares of RXDX. Numeric Investors LLC purchased a new stake in shares of Ignyta in the second quarter valued at approximately $126,000. Legal & General Group Plc boosted its stake in shares of Ignyta by 71.9% in the second quarter. Legal & General Group Plc now owns 12,681 shares of the biopharmaceutical company’s stock valued at $131,000 after buying an additional 5,306 shares in the last quarter. Virtu KCG Holdings LLC purchased a new stake in shares of Ignyta in the second quarter valued at approximately $132,000. Trexquant Investment LP purchased a new stake in shares of Ignyta in the third quarter valued at approximately $152,000. Finally, LMR Partners LLP purchased a new stake in shares of Ignyta in the third quarter valued at approximately $169,000. Hedge funds and other institutional investors own 72.28% of the company’s stock.
RXDX has been the topic of a number of research analyst reports. SunTrust Banks downgraded Ignyta from a “buy” rating to a “hold” rating and boosted their target price for the stock from $25.00 to $27.00 in a research report on Tuesday, December 26th. Zacks Investment Research upgraded Ignyta from a “hold” rating to a “buy” rating and set a $18.00 target price on the stock in a research report on Tuesday, November 14th. ValuEngine upgraded Ignyta from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. Cantor Fitzgerald reiterated a “hold” rating and set a $27.00 target price on shares of Ignyta in a research report on Friday. Finally, Ladenburg Thalmann Financial Services boosted their target price on Ignyta from $20.25 to $31.00 in a research report on Wednesday, October 18th. Seven investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. Ignyta presently has a consensus rating of “Hold” and an average price target of $27.00.
COPYRIGHT VIOLATION WARNING: This story was first reported by Watch List News and is the property of of Watch List News. If you are accessing this story on another website, it was illegally stolen and republished in violation of United States and international copyright & trademark laws. The original version of this story can be viewed at https://www.watchlistnews.com/gamco-investors-inc-et-al-invests-1-96-million-in-ignyta-inc-rxdx/1860946.html.
Ignyta, Inc is a biotechnology company. The Company is focused on precision medicine in oncology. The Company is pursuing an integrated therapeutic (Rx) and companion diagnostic (Dx) strategy for treating cancer patients. The Company’s pipeline includes various compounds, such as entrectinib, RXDX-105, taladegib and RXDX-106.
Want to see what other hedge funds are holding RXDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ignyta Inc (NASDAQ:RXDX).
Receive News & Ratings for Ignyta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ignyta and related companies with MarketBeat.com's FREE daily email newsletter.